UNSPSC 51383905: Lysine clonixinate

This classification denotes a non-morphinic analgesic with the molecular formula C13H11ClN2O2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06PW4M190R, chemically known as 3-pyridinecarboxylic acid, 2-((3-chloro-2-methylphenyl)amino)-, compd. with l-lysine (1:1) but generally known as lysine clonixinate, which bears US NIH Compound Identifier 3080836. European Medicines Agency schedules Lysine clonixinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01363MIG.

SMILES: CC1=C(C=CC=C1Cl)NC2=C(C=CC=N2)C(=O)O.C(CCN)CC(C(=O)O)N.

UNSPSC 51383905 Lysine clonixinate is a Commodity code that does not match the work actually being solicited under it in recent state and local opportunities. The code nominally describes a specific pharmaceutical active ingredient, but the three recent opportunities posted under this code—naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracts—involve drug procurement, pharmacy benefit management, and supply-chain contracting rather than lysine clonixinate specifically. The mismoric tagging suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical acquisition rather than purchasing the named ingredient. State and local buying under this code spans county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP), indicating fragmented governance with no dominant repeat buyer.

Recent activity concentrates in Florida and Texas, with multistate reach through MMCAP participation across Oregon and Minnesota. Seminole County issued IFB 60459723LAS (response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county's community health building, electronic bidding, and a two-year initial term plus one-year renewal option. Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs for self-insured health plans, signaling early-stage procurement planning rather than a formal contract award. Minnesota MMCAP, through the Department of Administration's Office of State Procurement, issued RFP S1070000015802 (response deadline March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluations weighted 75 percent on price competitiveness, 10 percent on fixed pricing structure, and smaller weights on administrative compliance and EDI capability.